Drug intelligence / Profile preview

HC-SVT-1001

Development stage: Phase 2
Lead developer: Laboratorios Salvat
Modality: Cell Therapies
Administration: Implant

Overview

HC-SVT-1001 is an autologous cell therapy product developed by Salvat for the surgical treatment of atrophic pseudarthrosis (nonunion) of long bones. It consists of ex vivo expanded adipose-derived mesenchymal stem cells (AD-MSCs) that are combined with a tricalcium phosphate (TCP) biomaterial scaffold. The AD-MSCs provide osteogenic potential by differentiating into bone-forming cells and secreting regenerative growth factors, while the TCP serves as an osteoconductive scaffold to support structural integrity and bone ingrowth at the site of the nonunion. This combination is applied locally during a single surgical intervention to promote bone healing in patients where natural repair has failed.

Other names: Autologous fat stem adult mesenchymal cells expanded and combined with a tricalcium phosphate biomaterial

Beyond the preview

Go deeper on HC-SVT-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC-SVT-1001.